Effects of Beta-blockade on Platelet Aggregation in Acute Coronary Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Investigators will test the hypothesis that nonselective beta-blockers would have a more pronounced effect on platelet aggregation than selective beta-blockers in patients with acute coronary syndrome treated with dual anti platelet therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes

NCT00123604

Hypertension Type 2 Diabetes Mellitus

COMPLETED PHASE4

Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure

NCT01499134

Peripheral Artery Disease Hypertension

COMPLETED PHASE3

Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart

NCT01798992

Idiopathic Dilated Cardiomyopathy

COMPLETED PHASE4

Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris

NCT02547597

Stable Angina Pectoris

COMPLETED PHASE4

Real World Assessment of Effects of Beta-blockers on Patients With Acute Coronary Syndrome

NCT03669991

Acute Coronary Syndrome

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In patients with acute coronary syndrome (ACS) beta-blockers are recommended for secondary prevention. It is known that catecholamine levels can potentiate platelet reactivity and beta-blocking agents may also affect platelet aggregation. This effect is mainly mediated by adrenergic receptors on platelets. This suggests that nonselective beta-blockers would have a more pronounced effect on platelet aggregation than selective beta-blockers. However, little is known about the effect of beta-blockers on platelet aggregation in patients with cardiovascular disease and, to date, nothing is known in the setting of ACS.

The aim of the present study is to evaluate the effect of selective and nonselective beta-blockers on platelet aggregation in ACS patients treated with dual anti platelet therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Carvedilol

Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume carvedilol.

Group Type ACTIVE_COMPARATOR

Carvedilol

Intervention Type DRUG

Patients randomized to this group will receive carvedilol at the highest dose tolerated

Metoprolol

Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume metoprolol.

Group Type ACTIVE_COMPARATOR

Metoprolol

Intervention Type DRUG

Patients randomized to this group will receive metoprolol at the highest dose tolerated

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carvedilol

Patients randomized to this group will receive carvedilol at the highest dose tolerated

Intervention Type DRUG

Metoprolol

Patients randomized to this group will receive metoprolol at the highest dose tolerated

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Selective beta-blocker Non Selective beta-blocker

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute Coronary Syndrome
* Current dual anti platelet treatment with acetylsalicylic acid and Ticagrelor

Exclusion Criteria

* ongoing prasugrel, ticlopidine or clopidogrel therapy
* Creatinine Clearance \< 30 ml/min/1.73mm2
* Moderate to severe anemia Hemoglobin \< 10 mg/dl
* Platelet count \>600000/mm3 or \<150000/mm3 or hematocrit \>50% or \<25%
* concomitant neoplastic or immune-mediated pathologies
* severe pulmonary pathologies
* contraindication to beta blocker therapy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No